@Tooheys8
Happy to be corrected, I suspect it is basically because it provides 'immediate access' to a much larger patient 'data-set' to move the 'breadth' of the testing/assessments forward far more quickly than waiting (and paying) for access to 'fresh' new-samples as they become available...
Reading between the lines, it seems exosomes have a 'shelf-life' as such, so will basically required UQ & IIQ to 'revert' to basically acquiring access to 'fresh samples' on an ongoing basis to move the test forward (get 'statistical runs' on the board with a significant sample size), collate and then, present to industry, hence the H2FY24 delay-statement...
ML
- Forums
- ASX - By Stock
- IIQ
- Ann: EXO-OC PROGRAM COMPLETES SERUM EQUIVALENCE STUDY
Ann: EXO-OC PROGRAM COMPLETES SERUM EQUIVALENCE STUDY, page-13
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
(20min delay)
|
|||||
Last
48.0¢ |
Change
-0.020(4.00%) |
Mkt cap ! $53.53M |
Open | High | Low | Value | Volume |
48.0¢ | 50.0¢ | 47.5¢ | $64.20K | 132.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 41187 | 47.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.5¢ | 10000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 41187 | 0.475 |
1 | 25000 | 0.470 |
3 | 13650 | 0.465 |
4 | 35410 | 0.460 |
4 | 37593 | 0.455 |
Price($) | Vol. | No. |
---|---|---|
0.485 | 10000 | 2 |
0.500 | 20153 | 2 |
0.505 | 28000 | 3 |
0.510 | 20000 | 2 |
0.515 | 8898 | 1 |
Last trade - 15.59pm 01/10/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online